相关实验视频
Updated: Jan 17, 2026

09:36
Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
27.7K
根据体重历史对肥胖的分类:对肥胖患者的看法
Bruno Halpern1, Simone van de Sande-Lee2, Maria Edna de Melo3
1Obesity Center, Nove de Julho Hospital, São Paulo, Brazil.
Clinical obesity
|January 14, 2026
概括
提出了基于最大终身体重的新肥胖分类. 患有肥胖症的人 (PwO) 发现这种分类对治疗,目标设定和减少耻辱感有用.
科学领域:
- 肥胖医学 肥胖医学
- 临床心理学 临床心理学
背景情况:
- 巴西医学协会为年龄在18-65岁的成年人提出了一种新型的肥胖分类系统,专注于最大终身体重.
- 该系统将肥胖个体 (PwO) 的体重减轻归类为"减轻"或"控制"的肥胖.
- 关于PwO对这种新分类的看法存在有限的数据.
研究的目的:
- 探索肥胖患者 (PwO) 关于基于最大终身体重的新分类系统的看法.
- 评估这种分类对普华永道关于肥胖治疗,动机和目标设定观点的潜在影响.
主要方法:
- 对500个普华永道公司进行了一项横截面的在线调查.
- 参与者得到了新分类系统的解释和临床案例.
- 收集的数据包括医疗保健专业人员 (HCP) 对最大体重的先前询问和参与者对新分类的回应.
主要成果:
- 64%的PwO表示从来没有被医疗人员询问过他们的最大体重.
- 在分类后,82%的人认为它有助于改变观念,66%的人感到鼓励寻求治疗,63%的人认为它将有助于治疗维护.
- 74%的受访者感到更好地达到"控制肥胖"的状态,即使体重减轻不足最佳水平.
- 大多数人同意它可以帮助设定现实的目标 (77%) 和减少HCP偏见 (69%).
结论:
- 患有肥胖症的人 (PwO) 积极地看待新的基于最大寿命体重的分类.
- 该分类被视为有利于鼓励寻求治疗,改善治疗坚持,并减少与肥胖相关的耻辱感.
- 这种系统可以促进更现实的目标设定,并减轻医疗保健专业人员的偏见.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
Assessment of the Gastrointestinal System II: Health Perception Pattern
455
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
Health Perception Patterns
Health perception patterns offer valuable insights into a patient's lifestyle habits and how they may impact their GI health. These patterns include:
455
Heart Failure IV: Classification and Diagnostic Evaluation
321
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
321
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169

